Total Funding
33
50
Total FundingSeries B raised
Growth Score
-2 pts
Heat Score
-12 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
77944
MAXONA is a pharmaceutical company that develops and commercializes a portfolio of novel therapeutics for the treatment of pain.
- Shawn Fatholahi: Founder, President, and CEO
Richard Brand: Chief Financial OfficerPast Role: Proto, Capital Markets Advisor, Director and Acting CFO
About the Company
MAXONA is a pharmaceutical company that develops and commercializes a portfolio of novel therapeutics for the treatment of pain. It is developing MAX-001 as the first novel therapeutic alternative to opioids and NSAIDs for the treatment of pain. While the U.S. is currently experiencing an opioid abuse epidemic, there has been very limited
innovation to address the needs of millions of Americans suffering from acute and chronic pain. Hence, there is a significant need for safe and efficacious alternative analgesics. MAX-001 is an ex-US marketed non-opioid, non-NSAID analgesic New Chemical Entity that aims to fundamentally address the shortcomings of existing therapies.
The company was founded in 2015 and is based in Malvern, Pennsylvania.
